Pediatric Speech Therapy Session Frequency and Speech Outcomes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Virginia Van Epps, M.Ed.
- Phone Number: (860) 837-5903
- Email: Vvanepps@connecticutchildrens.org
Study Locations
-
-
Connecticut
-
Hartford, Connecticut, United States, 06106
- Connecticut Children's Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Medical order for speech therapy
- Patients eligible for speech therapy at Connecticut Children's (qualify for receptive, expressive language and/or articulation therapy)
- Diagnosis of communication disorder.ICD-10 codes will be utilized pertaining to expressive, receptive language and articulation disorders (ICD-10 code specific to patient: F80.0, F80.1, F80.2, F80.4, F80.9, R47.89, R41.841)
- Patient recommended for individual (i.e. not group) treatment
- 18 months to 16 years of age
- Completed 1 plan of care (POC) with a duration of 8 sessions
- Attended at least 80% of scheduled visits during their plan of care period (still completing 8 sessions of therapy, may have extended time to completion).
- Services for a full 8-session plan of care.
Exclusion Criteria:
- - Seeking speech therapy care for treatment of disorders related to diagnosis of voice, feeding, fluency, and/or cognition
- Patient unable to complete standardized tests (EOWPVT-4, ROWPVT-4, GFTA-3, REEL-4)
- Patients in group speech therapy
- Patients younger than 18 months or older than 16 years of age
- Not willing to complete a full POC (8 sessions)
- Unable/unwilling to attend 80% of scheduled visits
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Every-other-week therapy with home programming
Receipt of standard speech therapy care (every-other-week) for 8.0 sessions
|
Delivery of speech therapy services
|
|
Experimental: Weekly therapy with home programming
Receipt of speech therapy care (every week) for 8.0 sessions
|
Delivery of speech therapy services
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Articulation and intelligibility
Time Frame: Baseline, immediately after treatment (up to 4 months)
|
Scores on the following standardized measures: Goldman Fristoe Test of Articulation- Third Edition (GFTA-3) ; Average Standard Score range is from 86-114; an increase in standard score indicates improvement in intelligibility.
|
Baseline, immediately after treatment (up to 4 months)
|
|
Change in Receptive vocabulary skills
Time Frame: Baseline, immediately after treatment (up to 4 months)
|
Scores on the following standardized measure: Receptive One Word Picture Vocabulary Test- Fourth Edition (ROVPVT-4); Average Standard Score range is from 85-115; an increase in standard score indicates improvement in understanding vocabulary.
|
Baseline, immediately after treatment (up to 4 months)
|
|
Change in Expressive vocabulary skills
Time Frame: Baseline, immediately after treatment (up to 4 months)
|
Scores on the following standardized measure: Expressive One Word Picture Vocabulary Test- Fourth Edition (EOWPVT-4); Average Standard Score range is from 85-115; an increase in standard score indicates improvement in understanding or labeling vocabulary.
|
Baseline, immediately after treatment (up to 4 months)
|
|
Change in Receptive and expressive early language skills
Time Frame: Baseline, immediately after treatment (up to 4 months)
|
Scores on the following standardized measures: Receptive-Expressive Emergent Language Scale- Fourth Edition (REEL-4); Average Standard Score range is from 90-109; an increase in standard score indicates improvement in language ability score.
|
Baseline, immediately after treatment (up to 4 months)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Home Exercise Plan (HEP) provision
Time Frame: up to 4 months
|
Parent-reported compliance with home therapy programming
|
up to 4 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Virginia Van Epps, M.Ed., Connecticut Children's Medical Center
- Study Director: Mary Dortenzio, MS, Connecticut Children's Medical Center
- Study Director: Jodi Urzua, MS, Connecticut Children's Medical Center
- Study Director: Emma Mendillo, MA, Connecticut Children's Medical Center
- Study Director: Morgan Daur-Schierholz, MS, Connecticut Children's Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Nervous System Diseases
- Mental Disorders
- Neurobehavioral Manifestations
- Neurodevelopmental Disorders
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Communication Disorders
- Therapeutics
- Patient Care
- Rehabilitation
- Aftercare
- Continuity of Patient Care
- Rehabilitation of Speech and Language Disorders
- Speech Therapy
Other Study ID Numbers
Other Study ID Numbers
- 22-160
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.